Wedbush began coverage on shares of Cartesian Therapeutics (NASDAQ:RNAC - Free Report) in a research note issued to investors on Wednesday, Marketbeat Ratings reports. The firm issued an outperform rating and a $38.00 target price on the stock. Wedbush also issued estimates for Cartesian Therapeutics' Q2 2025 earnings at ($0.74) EPS, Q3 2025 earnings at ($0.73) EPS, Q4 2025 earnings at ($0.54) EPS, FY2025 earnings at ($2.65) EPS, Q1 2026 earnings at ($0.54) EPS, Q2 2026 earnings at ($0.55) EPS, Q3 2026 earnings at ($0.56) EPS, Q4 2026 earnings at ($0.51) EPS, FY2026 earnings at ($2.16) EPS, FY2027 earnings at ($2.18) EPS, FY2028 earnings at ($2.64) EPS and FY2029 earnings at ($2.91) EPS.
Several other brokerages have also weighed in on RNAC. HC Wainwright reissued a "buy" rating and issued a $40.00 price objective on shares of Cartesian Therapeutics in a report on Wednesday, April 9th. Needham & Company LLC lowered their price objective on Cartesian Therapeutics from $41.00 to $40.00 and set a "buy" rating for the company in a report on Thursday, May 8th. One research analyst has rated the stock with a hold rating and five have given a buy rating to the company. Based on data from MarketBeat, Cartesian Therapeutics currently has an average rating of "Moderate Buy" and an average target price of $40.00.
Check Out Our Latest Stock Report on RNAC
Cartesian Therapeutics Stock Performance
Shares of NASDAQ RNAC traded down $0.22 during midday trading on Wednesday, reaching $13.32. 54,112 shares of the company's stock were exchanged, compared to its average volume of 99,154. Cartesian Therapeutics has a 52-week low of $8.46 and a 52-week high of $26.50. The stock has a market capitalization of $345.71 million, a PE ratio of -0.25 and a beta of 0.36. The business's fifty day moving average price is $10.46 and its two-hundred day moving average price is $14.17.
Cartesian Therapeutics (NASDAQ:RNAC - Get Free Report) last announced its earnings results on Thursday, May 8th. The company reported ($0.68) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.61) by ($0.07). The firm had revenue of $1.10 million during the quarter, compared to analyst estimates of $0.69 million. Analysts predict that Cartesian Therapeutics will post 4.56 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Cartesian Therapeutics
Institutional investors have recently made changes to their positions in the stock. Virtus ETF Advisers LLC bought a new position in shares of Cartesian Therapeutics during the fourth quarter valued at approximately $63,000. Wells Fargo & Company MN boosted its position in shares of Cartesian Therapeutics by 112.7% during the fourth quarter. Wells Fargo & Company MN now owns 4,847 shares of the company's stock worth $87,000 after buying an additional 2,568 shares during the period. Corebridge Financial Inc. boosted its position in shares of Cartesian Therapeutics by 32.6% during the fourth quarter. Corebridge Financial Inc. now owns 5,122 shares of the company's stock worth $92,000 after buying an additional 1,258 shares during the period. AlphaQuest LLC acquired a new position in shares of Cartesian Therapeutics during the first quarter worth approximately $95,000. Finally, Deutsche Bank AG boosted its position in shares of Cartesian Therapeutics by 104.1% during the first quarter. Deutsche Bank AG now owns 7,424 shares of the company's stock worth $98,000 after buying an additional 3,786 shares during the period. 86.95% of the stock is owned by institutional investors.
Cartesian Therapeutics Company Profile
(
Get Free Report)
Cartesian Therapeutics, Inc, a clinical-stage biotechnology company, engages in the provision of mRNA cell therapies for the treatment of autoimmune diseases. It develops Descartes-08, an autologous anti-BCMA RNA-engineered chimeric antigen receptor T-cell therapy, currently under Phase 2b clinical development for generalized myasthenia gravis, as well as for patients with systemic lupus erythematosus, and myeloma autoimmune basket trials for other autoimmune diseases.
Read More

Before you consider Cartesian Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cartesian Therapeutics wasn't on the list.
While Cartesian Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.